Boston Scientific Expects Q3 FY23 Revenue Growth Guidance Of 8.5%-10.5% (Reported) And 7%-9% (Organic); It Forecasts Adjusted EPS Of $0.46-$0.48 Vs. Consensus Of $0.48
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific has provided its Q3 FY23 revenue growth guidance of 8.5%-10.5% (reported) and 7%-9% (organic). The company also forecasts an adjusted EPS of $0.46-$0.48, which is in line with the consensus of $0.48.
July 27, 2023 | 10:43 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Boston Scientific's Q3 FY23 revenue growth and EPS forecast aligns with market expectations, which may not significantly impact its stock price in the short term.
Boston Scientific's Q3 FY23 revenue growth and EPS forecast are in line with market expectations. This suggests that the market has already priced in this information, and therefore, it may not have a significant impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100